Furen Pharmaceutical Group Industry Co Ltd (600781)

Shanghai

Currency in CNY

0.77

0.00(0.00%)

Closed19/06

Fair Value

Day's Range

0.74

0.84

52 wk Range

0.74

0.84

600781 Income Statement

Featured here, the Income Statement (earnings report) for Furen Pharmaceutical Group Industry Co Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2013

31/12

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

Total Revenues

6,317.31

5,171.09

2,890.52

1,512.5

1,468.67

Total Revenues Growth

+8.92%

-18.14%

-44.1%

-47.67%

-2.9%

Cost Of Revenues

3,546.25

2,950.86

1,650.13

1,289.98

746.77

Gross Profit

2,771.06

2,220.23

1,240.38

222.52

721.9

Gross Profit Growth

+18.63%

-19.88%

-44.13%

-82.06%

+224.42%

Gross Profit Margin %

43.86%

42.94%

42.91%

14.71%

49.15%

Other Operating Expenses, Total

1,437.91

1,224.01

1,146.12

1,519.95

2,370.11

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+23.17%	-14.88%	-6.36%	+32.62%	+55.93%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	228.94	212.7	122.18	59.29	45.11
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,125.17	980.96	978.14	1,438.86	2,286.05
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	83.79	30.36	45.8	21.8	38.95

Operating Income

1,333.15

996.22

94.27

-1,297.43

-1,648.21

Operating Income Growth

+14.1%

-25.27%

-90.54%

-1,476.3%

-27.04%

EBIT Margin %

21.1%

19.27%

3.26%

-85.78%

-112.22%

Net Interest Expenses

-215.88

-347.24

-635.74

-729.64

-692.23

Net Interest Expenses Growth

-16.56%

-60.85%

-83.08%

-14.77%

+5.13%

Interest Expense, Total

-231.99

-353.5

-635.76

-729.78

-692.5

Interest And Investment Income

16.11

6.25

0.02

0.13

0.27

Other Non Operating Expenses, Total

-18.59

-12.33

-734.95

-1,297.99

-468.45

EBT, Excl. Unusual Items

1,098.68

636.65

-1,276.42

-3,325.06

-2,808.89

Gain (Loss) On Sale Of Assets

-2.17

7.3

-149.53

0.01

0.21

Other Unusual Items, Total

11.16

7.28

8.57

-31.82

-29.29

EBT, Incl. Unusual Items

1,107.66

651.23

-1,417.38

-3,356.88

-2,837.96

EBT, Incl. Unusual Items Growth

+15.01%

-41.21%

-317.65%

-136.84%

+15.46%

EBT, Incl. Unusual Items Margin

17.53%

12.59%

-49.04%

-221.94%

-193.23%

Income Tax Expense

214.42

190.12

-86.15

-107.34

8.18

Net Income to Company

893.25

461.11

-1,331.23

-3,249.54

-2,846.15

Minority Interest

-4.69

-0.11

38.71

50.5

37.24

Net Income

888.56

460.99

-1,292.52

-3,199.05

-2,808.91

Net Income Growth

+126.67%

-48.12%

-380.38%

-147.5%

+12.2%

Net Income Margin %

14.07%

8.91%

-44.72%

-211.51%

-191.26%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

888.56

460.99

-1,292.52

-3,199.05

-2,808.91

Basic EPS - Continuing Operations

1.42

0.74

-2.06

-5.18

-4.48

Basic EPS - Continuing Operations Growth

+51.06%

-47.89%

-378.38%

-151.46%

+13.51%

Diluted EPS - Continuing Operations

1.42

0.74

-2.06

-5.18

-4.48

Diluted EPS - Continuing Operations Growth

+51.06%

-47.89%

-378.38%

-151.46%

+13.51%

Basic Weighted Average Shares Outstanding

625.74

622.96

627.44

617.58

626.99

Diluted Weighted Average Shares Outstanding

625.74

622.96

627.44

617.58

626.99

Dividend Per Share

0.1

-

-

-

-

Dividend Per Share Growth

-21.88%

-

-

-

-

EBITDA

1,686.08

1,380.01

474.04

-903.57

-1,274.39

EBITDA Growth

+12.65%

-18.15%

-65.65%

-290.61%

-41.04%

EBITDA Margin %

26.69%

26.69%

16.4%

-59.74%

-86.77%

EBIT